

## Special Issue

# Neuropsychopharmacology in Mood Disorders

### Message from the Guest Editor

Despite the detrimental effect of mood disorders including major depressive disorder (MDD) and bipolar disorder (BD), a large proportion of patients with mood disorders still do not experience sufficient treatment response. Countless novel therapeutic agents were developed for the treatment of MDD and BD. However, monoamine hypothesis remains one of the most important neurobiologies of MDD. Lithium, “an oldie but a goodie”, is still the most effective pharmacological agent for BD. From the other perspective, the recent approval of esketamine opened a new door for the treatment of MDD. By targeting NMDA receptors rather than monoamine transporters/receptors. Recent studies showed the importance of neuroplasticity and neuroinflammation in the pathophysiology of BD and MDD. With the rise of biomarkers, multiple studies are conducted for enhanced stratification and treatment monitoring in patients with mood disorders. This Special Issue aims to highlight the research, developmental, and clinical trend of neuropsychopharmacology in mood disorders. Readers will also be given insight into the prospect of neuropsychopharmacology in mood disorders by understanding its past.

### Guest Editor

Dr. Sheng-Min Wang

Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

### Deadline for manuscript submissions

closed (31 January 2024)



## Brain Sciences

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.6  
Indexed in PubMed



[mdpi.com/si/122270](https://mdpi.com/si/122270)

*Brain Sciences*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[brainsci@mdpi.com](mailto:brainsci@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[brainsci](https://brainsci.mdpi.com)





# Brain Sciences

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.6  
Indexed in PubMed



[mdpi.com/journal/  
brainsci](https://mdpi.com/journal/brainsci)



## About the Journal

### Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

---

### Editor-in-Chief

Prof. Dr. Stephen D. Meriney

Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA  
15260, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYINDEX, PsycInfo, CAPlus / SciFinder, and other databases.

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.2 days after submission; acceptance to publication is undertaken in 1.9 days (median values for papers published in this journal in the first half of 2025).

#### Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.